- Pre-IND meeting with FDA scheduled for January for lead antibody program
TORONTO, Dec. 5 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it has entered into a manufacturing supply and technology transfer agreement for its CD44 Cancer Stem Cell antibody with Avid Bioservices, a company providing cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid has begun manufacturing a supply of the drug for human clinical trials which ARIUS plans to initiate in 2008. ARIUS also announced it has scheduled a pre-IND meeting with the FDA that will take place in January.
"The initiation of manufacturing and the scheduling of our pre-IND meeting with the FDA in January reflect the significant progress we have made with our CD44 Cancer Stem Cell program," said Dr. David Young, President and Chief Executive Officer of ARIUS. "Avid has proven expertise in the scale-up and manufacture of clinical and commercial grade antibodies and will provide us with a supply of our CD44 targeting drug to initiate human clinical trials in 2008, subject to the clearance of our IND by the FDA."
"This new manufacturing agreement is the result of the solid working relationship we have developed with the ARIUS team," said F. David King, Vice President, Business Development of Avid. "Our goal is to form strategic partnerships with innovative life sciences companies like ARIUS, serving as a premier service provider by seamlessly integrating our experience and capabilities with our clients' needs."
ARIUS is advancing the formal pre-clinical toxicology program for its
lead CD44 Cancer Stem Cell program, an anti-cancer antibody targeting a
novel epitope of CD44 found in breast, colon, and prostate cancers.
Pre-clinical data from a dose-ranging pilot toxicology study in non-human
|SOURCE ARIUS Research Inc.|
Copyright©2007 PR Newswire.
All rights reserved